Collegium Pharmaceutical Analyst Ratings
Collegium Pharmaceutical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/25/2023 | 53.13% | Needham | $35 → $36 | Maintains | Buy |
| 08/04/2023 | — | HC Wainwright & Co. | Reiterates | → Neutral | |
| 08/04/2023 | 48.87% | Needham | → $35 | Reiterates | Buy → Buy |
| 05/30/2023 | 48.87% | Needham | → $35 | Reiterates | Buy → Buy |
| 05/05/2023 | 48.87% | Needham | → $35 | Reiterates | → Buy |
| 05/02/2023 | 27.61% | Jefferies | → $30 | Assumes | → Buy |
| 04/19/2023 | 48.87% | Needham | → $35 | Reiterates | → Buy |
| 02/24/2023 | 48.87% | Needham | → $35 | Reiterates | → Buy |
| 02/08/2023 | 48.87% | Needham | → $35 | Reiterates | → Buy |
| 01/05/2023 | 48.87% | Needham | $34 → $35 | Maintains | Buy |
| 11/04/2022 | 44.62% | Needham | $36 → $34 | Maintains | Buy |
| 08/08/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 04/06/2022 | 53.13% | Needham | $34 → $36 | Maintains | Buy |
| 02/22/2022 | 78.65% | Piper Sandler | $36 → $42 | Maintains | Overweight |
| 02/15/2022 | 23.35% | HC Wainwright & Co. | $26 → $29 | Maintains | Buy |
| 02/15/2022 | 44.62% | Needham | $28 → $34 | Maintains | Buy |
| 11/15/2021 | 19.1% | Needham | $26 → $28 | Maintains | Buy |
| 11/05/2021 | 10.59% | Needham | $32 → $26 | Maintains | Buy |
| 08/06/2021 | -6.42% | Cantor Fitzgerald | $30 → $22 | Downgrades | Overweight → Neutral |
| 08/06/2021 | 36.11% | Needham | $34 → $32 | Maintains | Buy |
| 08/06/2021 | 19.1% | HC Wainwright & Co. | $33 → $28 | Maintains | Buy |
| 01/11/2021 | 40.37% | HC Wainwright & Co. | $29 → $33 | Maintains | Buy |
| 11/09/2020 | 23.35% | HC Wainwright & Co. | $31 → $29 | Maintains | Buy |
| 07/14/2020 | -65.97% | BWS Financial | → $8 | Initiates Coverage On | → Sell |
| 05/27/2020 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 05/08/2020 | 53.13% | Needham | $38 → $36 | Maintains | Buy |
| 02/12/2020 | 48.87% | Piper Sandler | $27 → $35 | Maintains | Overweight |
| 02/07/2020 | 27.61% | Cantor Fitzgerald | $24 → $30 | Maintains | Overweight |
| 02/07/2020 | 61.63% | Needham | $36 → $38 | Maintains | Buy |
| 01/08/2020 | 53.13% | Needham | $28 → $36 | Maintains | Hold |
| 08/08/2019 | 2.08% | Cantor Fitzgerald | $35 → $24 | Reiterates | → Overweight |
| 05/03/2019 | -2.17% | HC Wainwright & Co. | → $23 | Assumes | → Buy |
| 04/12/2019 | — | Janney Montgomery Scott | Assumes | → Buy | |
| 03/20/2019 | -6.42% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月25日 | 53.13% | 李約瑟 | $35→$36 | 維護 | 買 |
| 08/04/2023 | - | HC Wainwright公司 | 重申 | →中性 | |
| 08/04/2023 | 48.87% | 李約瑟 | →$35 | 重申 | 購買→購買 |
| 2023年05月30日 | 48.87% | 李約瑟 | →$35 | 重申 | 購買→購買 |
| 05/05/2023 | 48.87% | 李約瑟 | →$35 | 重申 | →購買 |
| 05/02/2023 | 27.61% | 傑富瑞 | →$30 | 假設 | →購買 |
| 04/19/2023 | 48.87% | 李約瑟 | →$35 | 重申 | →購買 |
| 02/24/2023 | 48.87% | 李約瑟 | →$35 | 重申 | →購買 |
| 02/08/2023 | 48.87% | 李約瑟 | →$35 | 重申 | →購買 |
| 01/05/2023 | 48.87% | 李約瑟 | $34→$35 | 維護 | 買 |
| 11/04/2022 | 44.62% | 李約瑟 | $36→$34 | 維護 | 買 |
| 2022/08/08 | - | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 04/06/2022 | 53.13% | 李約瑟 | $34→$36 | 維護 | 買 |
| 02/22/2022 | 78.65% | 派珀·桑德勒 | $36→$42 | 維護 | 超重 |
| 02/15/2022 | 23.35% | HC Wainwright公司 | $26→$29 | 維護 | 買 |
| 02/15/2022 | 44.62% | 李約瑟 | $28→$34 | 維護 | 買 |
| 2021年11月15日 | 19.1% | 李約瑟 | $26→$28 | 維護 | 買 |
| 2021年11月05日 | 10.59% | 李約瑟 | $32→$26 | 維護 | 買 |
| 08/06/2021 | -6.42% | 康託·菲茨傑拉德 | $30→$22 | 評級下調 | 超重→中性 |
| 08/06/2021 | 36.11% | 李約瑟 | $34→$32 | 維護 | 買 |
| 08/06/2021 | 19.1% | HC Wainwright公司 | $33→$28 | 維護 | 買 |
| 2021/11/01 | 40.37% | HC Wainwright公司 | $29→$33 | 維護 | 買 |
| 11/09/2020 | 23.35% | HC Wainwright公司 | $31→$29 | 維護 | 買 |
| 07/14/2020 | -65.97% | BWS金融 | →$8 | 開始承保 | →銷售 |
| 05/27/2020 | - | 古根海姆 | 開始承保 | →中性 | |
| 05/08/2020 | 53.13% | 李約瑟 | $38→$36 | 維護 | 買 |
| 02/12/2020 | 48.87% | 派珀·桑德勒 | $27→$35 | 維護 | 超重 |
| 02/07/2020 | 27.61% | 康託·菲茨傑拉德 | $24→$30 | 維護 | 超重 |
| 02/07/2020 | 61.63% | 李約瑟 | $36→$38 | 維護 | 買 |
| 1/08/2020 | 53.13% | 李約瑟 | $28→$36 | 維護 | 保持 |
| 2019年08月08日 | 2.08% | 康託·菲茨傑拉德 | $35→$24 | 重申 | →超重 |
| 2019年05月03日 | -2.17% | HC Wainwright公司 | →$23 | 假設 | →購買 |
| 2019年4月12日 | - | 詹尼·蒙哥馬利·斯科特 | 假設 | →購買 | |
| 2019/03/20 | -6.42% | SunTrust Robinson Humphrey | →$22 | 開始承保 | →購買 |
What is the target price for Collegium Pharmaceutical (COLL)?
科萊姆製藥公司(Colcium Pharmtics)的目標價是多少？
The latest price target for Collegium Pharmaceutical (NASDAQ: COLL) was reported by Needham on August 25, 2023. The analyst firm set a price target for $36.00 expecting COLL to rise to within 12 months (a possible 53.13% upside). 11 analyst firms have reported ratings in the last year.
李約瑟於2023年8月25日報道了科爾製藥(納斯達克代碼：COL)的最新目標價。這家分析公司將目標價定為36.00美元，預計Coll將在12個月內上漲(可能上漲53.13%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Collegium Pharmaceutical (COLL)?
科萊姆製藥公司(Coll)最近的分析師評級是多少？
The latest analyst rating for Collegium Pharmaceutical (NASDAQ: COLL) was provided by Needham, and Collegium Pharmaceutical maintained their buy rating.
Needham提供了對科大藥業(納斯達克代碼：COL)的最新分析師評級，科大藥業維持其買入評級。
When is the next analyst rating going to be posted or updated for Collegium Pharmaceutical (COLL)?
科萊姆製藥(Coll)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Collegium Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Collegium Pharmaceutical was filed on August 25, 2023 so you should expect the next rating to be made available sometime around August 25, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與科萊姆製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Colcium Pharmtics的上一次評級是在2023年8月25日提交的，所以你應該預計下一次評級將在2024年8月25日左右的某個時候公佈。
Is the Analyst Rating Collegium Pharmaceutical (COLL) correct?
分析師對科爾製藥(Colcium Pharmtics)的評級正確嗎？
While ratings are subjective and will change, the latest Collegium Pharmaceutical (COLL) rating was a maintained with a price target of $35.00 to $36.00. The current price Collegium Pharmaceutical (COLL) is trading at is $23.51, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的大學制藥(COL)評級維持不變，目標價在35.00美元至36.00美元之間。科萊姆製藥公司目前的股價為23.51美元，超出了分析師的預測範圍。